

## **HHS Public Access**

Author manuscript *Med Care*. Author manuscript; available in PMC 2015 November 11.

Published in final edited form as:

Med Care. 2012 August ; 50(8): 676-684. doi:10.1097/MLR.0b013e3182551793.

# Are Characteristics of the Medical Home Associated with Diabetes Care Costs?

Thomas J. Flottemesch, PhD<sup>1</sup>, Sarah Hudson Scholle, MPH, DrPH<sup>2</sup>, Patrick J. O'Connor, MD<sup>1</sup>, Leif I. Solberg, MD<sup>1</sup>, Steve Asche, MA<sup>1</sup>, and L. Gregory Pawlson, MD, MPH<sup>2</sup> <sup>1</sup>HealthPartners Research Foundation, Minneapolis, MN

<sup>2</sup>National Committee for Quality Assurance, Washington, DC

### Abstract

**Objective**—To examine the relationship between primary care medical home clinical practice systems (PCMH clinical practice systems) corresponding to the domains of the Chronic Care Model and diabetes-related healthcare costs incurred by members of a health plan who have diagnosed Type 2 diabetes and received care at one of 27 Minnesota-based medical groups over a 12-month period.

**Study Design**—Cross-sectional analysis of patient-level cost data in relation to the presence of PCMH clinical practice systems by Chronic Care Model domain using the Physician Practice Connections Readiness Survey (PPC-RS).

**Methods**—Multivariate regressions adjusting for patient demographics, health status and comorbidities estimated the relationship between the presence of PCMH clinical practice systems as measured by the PPC-RS and three outcomes: total diabetes-related healthcare costs, ambulatory care management costs, and potentially avoidable costs (e.g. unscheduled inpatient and emergency care).

**Results**—Two domains of PCMH clinical practice systems as measured by the PPC-RS were significantly associated with reductions in potentially avoidable costs. These were Health Care Organization (p=.04) and clinical reminder systems in the Decision Support domain (p=.01). Compared to medical groups with only quality improvement, those with improved Health Care Organization defined as performance measurement and individual provider feedback averaged \$245/patient less. Similarly, medical groups with clinical reminders for counseling averaged \$338/ patient less.

**Conclusions**—PCMH clinical practice systems that correspond to some domains of the Chronic Care Model are related to reduced inpatient and emergency care costs. Further research is needed about how these systems impact costs over time.

Corresponding Author: Thomas J. Flottemesch, PhD, Research Associate, HealthPartners Research Foundation, PO Box 1524, MS 21111R; Minneapolis, MN 55440-1524, Tel: 952-967-1121, Fax: 951-967-5022, Thomas.J.Flottemesch@healthpartners.com. Disclosure: This work was supported by a grant from The Commonwealth Fund.

#### Keywords

medical home; clinical practice systems; decision support; utilization; diabetes; costs; chronic care model

#### Introduction

Healthcare spending continues to increase well beyond the rate of other sectors of our economy. Specific to this research, patients with diabetes consume 250% more healthcare resources compared to peers without diabetes.(1) Unfortunately, there have not been commensurate improvements in quality,(2–8) and there is ample evidence of variation in resource use and quality across physicians and medical groups.(9–13)

The concept of a Patient-Centered Medical Home (PCMH), which originated with the American Academy of Pediatrics in 1967, is receiving increased attention as a potential means to improve care.(14–20) Payers, purchasers, and policy makers see it as a vehicle for moderating costs and improving quality.(21–28) High functioning medical homes may facilitate the patient-centeredness in primary care resulting in improved patient satisfaction. (29) For example, adults reporting a usual source of care are 25% more likely to report positive clinician attributes(30), and reduced racial and ethnic disparities have also been identified.(31)

Clinical practice systems are recognized as an important component of the PCMH. NCQA has developed a tool, the Physician Practice Connection (PPC)®, that measures the use of defined practice systems and is being used in many of the PCMH pilot programs. (32–36) Prior research has indicated that use of some of the same clinical practice systems posited as part of the medical home, result in improved clinical care, such as in patients with diabetes. (37) Although some reports of implementation of PCMH like models of practice have reported cost reductions(38–43), studies linking the use of specific systems to resource use/ cost are lacking.(44)

In order to address this need, we conducted a secondary data analysis of the relationship between clinical practice systems and annual diabetes costs. The research described in this paper explores the relationship between the research version of the PPC tool, and costs of care for patients with diabetes. It focuses upon three outcomes: 1) total cost of care, 2) ambulatory management costs, and 3) potentially avoidable costs (e.g. unplanned hospital stays and/or emergency department use).

#### Methods

#### **Study Population and Data Sources**

We performed a retrospective analysis of cross-sectional data from 2005–06. The unit of analysis is diabetic patients enrolled in HealthPartners (HP), a large non-profit Minnesotabased insurer. All study subjects met the following criteria: (a) 12 months of continuous enrollment with less than a 15-day interruption, (b) age 19–75 years inclusive on 1/1/2005, (c) alive on 12/31/06, (d) a modified Charlson comorbidity score less than 3, and (e) an

established diagnosis as of the beginning of the 12-month period. The modified Charlson comorbidity score excluded diabetes as a condition in its calculation. Consistent with prior studies(9, 10, 45–48), patients with a score of 3 or greater were excluded because of the high likelihood of death and confounding disease burden. We defined diabetes using the following validated definition that closely matches that used in physician-level HEDIS diabetes quality measures: 1) one or more inpatient or two or more outpatient ICD-9 codes 250.xx, or 2) a filled prescription for a diabetes-specific medication other than a biguanide. Biguanide use required at least one 250.xx code, because it is used for other conditions. We excluded codes for gestational diabetes. This method is 94% sensitive with a positive predictive value of 0.94.(49)

Patients received primary care from one of 27 Minnesota-based primary care medical groups located in the Minneapolis/St. Paul metropolitan region. Patients were attributed to medical groups based primary care use as determined by evaluation and management codes (i.e. E&M codes).(50) A group needed to account for more than 50% of a patient's primary care for him/her to be attributed to a medical group. Those with less than 50% attributable to a single group were excluded. The average proportion of office visits attributable to a primary medical group was 67.5%. In Minnesota, most physicians practice in relatively large medical groups, usually consisting of multiple clinic sites.

Data came from two sources. Practice system measures came from a medical director survey, the PPC-RS. Diabetes related outcomes, patient demographics and diabetes-related costs came from health plan administrative databases. The study was reviewed, approved, and monitored by the HealthPartners Institutional Review Board.

**Measure of PCMH- The PPC-RS**—Using the framework of the Chronic Care Model and the PCMH(51), the Physician Practice Connections Readiness Survey (PPC-RS) is a tested and validated survey that measures the presence of clinical practice systems (Table 1) and forms the basis of the PPC-PCMH instrument used in NCQA qualification of practices as PCMH's.(37, 52, 53) It was completed by medical group medical directors in the summer of 2005. A full description of the tool as well as a crosswalk of the PPC-RS and the PPC-PCMH is available on request from one of the authors.

**HealthPartners (HP) Administrative Data**—HealthPartners administrative databases contain information regarding medical diagnoses and care, pharmacy fills, utilization, and costs. The total number of fills of outpatient pharmaceutical scripts by drug class was grouped into four categories: Glucose Lowering, Hypertension Control, Cholesterol Lowering, and Other. Some patients (148) did not have full prescription data due to payer mix (i.e. dual payer or pharmacy carve-out). These data were imputed using multiple regressions.(54–56) Quality diabetes care was defined by: glycated hemoglobin (A1c)<8%, systolic blood pressure (SBP)<130 mm Hg, and low-density lipoprotein (LDL) measure<100 mg/dl.

Our cost outcomes are based upon a standardized measure of utilization, the HealthPartners Relative Resource Value (HPRRV).(57–64) HPRRVs are based upon Centers for Medicare and Medicaid Services (CMS) relative value units (RVUs) but extend RVU measures to

include inpatient, outpatient surgery, emergency room services, scheduled outpatient, professional, and pharmacy services. Where a CMS weight does not exist, HPRRVs use the average billed amount from HealthPartners claims. Because HPRRVs value services similarly to RVUs, HPRRVs are convertable to dollars using the Medicare cost factor for the study year (i.e. 100 HPRRVs \$106).

Claims data were organized using Episode Symmetry (ESE) software.(65) For acute events, the ESE algorithm constructs episode treatment groups (ETGs) based upon serially occurring CPT and ICD codes. For chronic diseases like diabetes, the ESE algorithm groups all related E&M, ICD and CPT codes (lipid panels, insulin, emergency department visits, hospitalizations, etc.) occurring within a pre-defined time-window of 12 months. Utilization more closely associated with other conditions or triggered by acute events is allocated to separate ETGs.

**Study Outcomes**—This study focused on three outcomes: 1) total cost of care, 2) ambulatory management costs, and 3) potentially avoidable costs (disease-related unplanned hospital stays or emergency department use). A patient's total cost of care was defined as all diabetes-related costs occurring during the episode. Ambulatory management costs were defined as all discretionary healthcare resources attributable to primary care and management such as: a) claims from primary and specialty care services (clinic visit, scheduled radiographic procedures, labs performed on a outpatient bases, and outpatient prescriptions), and b) claims for scheduled inpatient procedures (surgical fees, hospital professional fees, and inpatient hospital costs). Potentially avoidable costs were utilization that the use of systems and the PCMH is intended to reduce. These are: a) service claims for emergency care attributable to diabetes (emergency transport charges, urgent care fees, emergency physician professional fees, imaging or lab charges), and b) hospital and other facility fees corresponding to that emergency care (unscheduled surgery, facility costs corresponding to an unscheduled inpatient stay, and transitional/step-down care).

**Final Sample**—We identified 2,183 patients with Type 2 diabetes who receiving over 50% of their primary care from a contracted medical group completing the PPC-RS. Of these, 175 were associated with a medical group whose PPC-RS responses were incomplete. This resulted in 2,008 patients from 27 medical groups in the final sample (Tables 1 and 2).

#### **Plan of Analysis**

We followed a bottom-up approach. First, we tested for significant variation at the medical group level using a likelihood ratio test set at the 5% level. Second, we constructed a baseline patient-level model. Covariates significant at the 10% level in univariate models were candidates for the multivariate model. Candidate covariates were screened for confounding and multicolinearity prior to development of the final multivariate model and appropriate adjustments taken. Covariates and interactions significant at the 10% and 5% level were retained, respectively. Third, PPC-RS systems scores were analyzed. Each domain score (*Health Care Organization, Delivery System Redesign, Clinical Information System, Decision Support, and Self Management Support*) and the overall PPC-RS score were considered in a separate models. Cross-level interactions with patient-level factors

significant at the 5% level were retained. Finally, a model incorporating all of the domain scores was fit.

Preliminary analysis indicated no significant proportion of the overall variation was attributed to medical group (ICC 0). Further, a generalized linear model with gammadistributed errors was found preferable to a log-transformed model.(66–70) To protect against heteroskedasticity, a robust covariance estimator was used.

Because only 781 (39%) of the included patients had potentially avoidable resource use, a two-part model was used. The first part estimated the likelihood of any utilization using a multivariate, logistic regression. The second modeled avoidable resource use among those with utilization. Our final cost estimates were derived by conditioning estimated costs effects upon estimated likelihood of any utilization.

#### Results

Table 2 provides information on the demographics, clinical characteristics, and utilization for our analytic sample. Subjects averaged 54 years, 42% were female, and the mean BMI=34.4 Kg/m2 (SD 7.6). Most had at lease one comorbid condition with hypertension (54%) being the most prevalent.

Costs, including pharmaceutical use, varied widely. Total costs averaged \$4,137, and were heavily skewed with a range from \$305 to \$73,029. Most (61%) had no potentially avoidable costs, and there was variation among those who did (range = \$47.07 to \$63,752.54).

The 27 medical groups varied in terms of their patient demographics and clinical practice system scores (Table 3). The average number of patients was 63 (range=8 to 179). The medical group median total per patient cost averaged \$3,243 (range \$2,091 to \$4,768). Median per patient ambulatory management costs were less variable (mean \$2,641, SD= \$531). The level of clinical practice systems implementation varied considerably. Overall PPC-RS system scores ranged from 32.2 to 95.8 with an average of 67.9.

Table 4 shows the cost relations between clinical practice systems and annual diabetesrelated costs. Although overall PPC-RS scores were associated with an apparent decrease in total, ambulatory, and potentially avoidable costs, none of these associations were statistically significant at the 5% level. The health care organization (HCO) domain score was not significantly associated with ambulatory management costs (p=.25); however, it was significantly associated with decreased potentially avoidable costs and total costs. A 10% increase in an HCO score (from 86 to 95) was associated with both a decreased likelihood (OR=.97, p=.04) and decreased amount (p=.04) of potentially avoidable costs for estimated overall per person decrease of \$25.20.

A clearer understanding this association comes from examining individual elements of the PPC-RS (Table 1). The HCO domain is composed of three questions: Formal Quality Improvement Activities (QI), Performance Measurement (PM), and Individual Feedback (IF). Only one medical group failed to engage in any activities, while three engaged in only

formal QI activities. One engaged in both QI and PM and the remaining 22 medical groups engaged in all three. After adjusting for patient age, gender, co-morbidities, smoking status, A1c level, LDL level, and prescription drug use, patients at the medical group with no QI activities averaged \$125 *more* per patient than those at the three medical groups with only formal QI activities. Patients at medical groups with both QI and PM averaged \$126 *less* than those at the three medical groups with only formal QI activities, and patients at the medical groups with all three HCO activities (QI, PM, and IF) averaged \$245 *less* than patients at the three medical groups with only QI. In other words if the five medical groups that currently do not began to engage in all three HCO activities there could be an estimated overall cost reduction of \$53,721, or 5% of the total costs incurred by the 275 patients within these five medical groups.

A similar relationship was observed with *Decision Support*. Patients who received care at medical groups with improved decision support had a significantly lower likelihood of incurring any potentially avoidable costs (OR=.94, p=.02) with no change in the average amount of avoidable costs (p=.86). This resulted in a net average marginal cost reduction of \$26 for every 10% increase in a medical group's decision support score. Although a seemingly small amount, individual components provide a clearer illustration of this association. Nine components comprise the *Decision Support* domain score (Table 1). All 27 medical groups have implemented age-appropriate preventive services and all but one has implemented evidence-based diabetes standards. The groups differ in the implementation of clinical reminders, alerts, and abnormal test protocols. After adjusting for age, gender, comorbidities, and pharmaceutical use, only clinical reminders for counseling had a significant cost association (p=.01) with the 18 medical groups (1,429 patients) with counseling reminders averaging \$337.93 per patient less than the 9 medical groups (579 patients) without this decision support system.

#### Discussion

This cross-sectional study suggests some office practice systems associated with the PCMH may moderate health care costs. Patients were less likely to have potentially avoidable costs such as emergency care and unscheduled hospital stays and were more likely to have lower overall costs when they received care from medical groups that had implemented PCMH-related systems in their practices such as formal quality improvement initiatives, individualized feedback, and clinician reminders.

However, we did not find a significant cost relationship between the implementation of systems and cost related to the direct management of diabetes in the clinic setting (Ambulatory Management Costs-Table 4). This is not surprising because implementation of systems in domains such as Delivery System Redesign, Clinical Information Systems, and Decision Support may be expected to *increase utilization* of some direct care resources (e.g. medication use or care management) in the short run (i.e. the one year period studied). Although higher delivery system redesign scores were significantly associated with increased ambulatory management costs (p=.01), the estimated monetary impact was small (\$.99/patient/year).

Prior studies that have attempted to correlate system use with medical costs are scarce. Studies by Gillies et al(71), and others(37, 52) have shown a relationship between quality and use of systems using a related instrument. An interesting set of related findings was reported in a recent paper by Scholle(72), indicating a negative relationship between quality of care using HEDIS quality measures in diabetes and resource use measures of total utilization of inpatient, surgical and procedures by the same patients at the health plan level. By contrast, a positive relationship was noted between quality of care and use of pharmacy resources in the same cohort of patients with diabetes.

These findings are preliminary, since they are based on a relatively small and limited sample of medical groups drawn from a single geographic region with a long- term emphasis upon improving diabetes care with results that are better than most other regions. In addition, the data are based only on insured patients and most of these medical groups have already achieved a significant level of PCMH clinical practice system implementation, so there is less variation in both factors being tested.

The cross-sectional design of the study prevents analysis of the potential impact of primary care medical home systems over time. Future studies are needed to determine the longitudinal impact of system redesign upon utilization and quality in a larger set of medical groups having greater variation in both systems and quality. Further, the study relied on medical directors' self-reports of the presence of clinical practice systems. Previous studies of the validation of this survey showed that medical directors were more likely to underreport systems in this community than to over-report them, at least when there was no financial incentive for the latter.[cites] Finally, there are many factors that can confound chronic disease care. We attempted to control for these by incorporating a variety of covariates in our final models such as age, gender, comorbidities, and pharmaceutical drug use. Nonetheless, this set of demographics was far from exhaustive, and we were unable to account for the impact of such factors as race and socio-economic status.

The study's findings regarding the impact of PCMH clinical practice systems upon costs may be conservative for other reasons. First, we examined costs directly attributable to diabetes. Most adults with diabetes have other chronic conditions that add substantially to their health care costs, and systems focused upon improving diabetes care are likely to also assist in managing these conditions.(51, 73) Additional research exploring whether improved clinical systems for one chronic disease assist in managing complex cases and further reduce total costs is needed.

Despite these limitations, these results raise a question about how much the implementation of the PCMH model could reduce the medical costs over which physicians may have the greatest direct control and benefit. The greatest opportunity for savings appears to be in potentially avoidable costs caused by unplanned hospitalizations and emergency department use. An inference building on this study, as well as prior studies linking broader use of systems with higher quality of care in diabetes is that the reduction in potentially avoidable costs is an indirect result of better ambulatory care management. The relationship between systems, quality and cost is far from simple and the current pioneering study provides only a starting point for more extensive and prospective evaluations of these interrelationships. We

suggest that planned medical home demonstrations should consider these possible competing cost patterns and relationships in their design and evaluation.

#### Conclusions

Some clinical practice systems appear to be associated with lower use of potentially avoidable care such as unplanned hospitalizations and emergency room visits. Efforts to promote and evaluate systematic care through the adoption of the Chronic Care Model and the Patient Centered Medical Home should include a controlled longitudinal evaluation of how these models of care are related to costs for managing chronic and preventive care as well as for costs for unexpected care such as unplanned hospitalizations and emergency visits.

#### Acknowledgments

The authors declare no conflicts of interest or financial interest other than recognizing that, as the developer and owner of the PPC-RS, NCQA is eager to encourage scientific analysis and debate about its validity and value. Thomas Flottemesch (who has received grant support for this study) had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. We would like to thank Melinda Abrams for her helpful review of the manuscript. We are grateful to Minnesota Community Measurement and James Chase, its Executive Director, for providing the quality data that allowed us to demonstrate these associations. We are also indebted to the medical directors and their organizations that all agreed to participate by completing the PPC-RS and consenting to our use of their MN CM data files. These medical groups are Affiliated Community Medical Centers, Allina Medical Clinic, Altru Health System, Aspen Medical Group, Brainerd Medical Center, P.A., Buffalo Clinic, P.A., Camden Physicians, CentraCare Health System, Columbia Park Medical Group, Dakota Clinic, Ltd., Fairview Health Services, Fairview Red Wing Health Services, Family Health Services of Minnesota, Fergus Falls Medical Group, PA, HealthEast Clinics, HealthPartners Central MN Clinics, HealthPartners Medical Group, Hennepin Faculty Associates, Hutchinson Medical Center, Lakeview Clinic, Ltd., Mankato Clinic, Ltd., Mayo Clinic, MeritCare Health System, Multicare Associates, North Clinic, North Memorial Health Care Clinic Services, Northstar Physicians, Northwest Family Physicians, Olmsted Medical Center, Park Nicollet Health Services, Ridgeview Care System, St. Cloud Medical Group, PA, St. Luke's Clinics, St. Mary's/ Duluth Clinic Health System, Stillwater Medical Group, SuperiorHealth Medical Group, University of Minnesota Physicians Family Medicine Clinics, Western Wisconsin Medical Associates, S.C. and Winona Clinic, Ltd.

#### References

- Selby JV, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care. 1997; 20(9):1396–402. [PubMed: 9283786]
- Solberg LI, Lyles CA, Shore AD, Lemke KW, Weiner JP. Is quality free? The relationship between cost and quality across 18 provider groups. Am J Manag Care. 2002; 8(5):413–22. [PubMed: 12019594]
- Scholle SH, Mardon R, Shih SC, Pawlson LG. The relationship between quality and utilization in managed care. Am J Manag Care. 2005; 11(8):521–7. [PubMed: 16095438]
- 4. Starfield B, Powe NR, Weiner JR, et al. Costs vs quality in different types of primary care settings. JAMA. 1994; 272(24):1903–8. [PubMed: 7990241]
- Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 2: health outcomes and satisfaction with care. Ann Intern Med. 2003; 138(4):288–98. [PubMed: 12585826]
- Fisher ES, Wennberg DE, Stukel TA, Gottlieb DJ, Lucas FL, Pinder EL. The implications of regional variations in Medicare spending. Part 1: the content, quality, and accessibility of care. Ann Intern Med. 2003; 138(4):273–87. [PubMed: 12585825]
- 7. Fisher ES, Wennberg JE. Health care quality, geographic variations, and the challenge of supplysensitive care. Perspect Biol Med. 2003; 46(1):69–79. [PubMed: 12582271]

- Casalino L, Gillies RR, Shortell SM, et al. External incentives, information technology, and organized processes to improve health care quality for patients with chronic diseases. Jama. 2003; 289(4):434–41. [PubMed: 12533122]
- 9. Gilmer T, O'Connor PJ. Cost effectiveness of diabetes mellitus management programs: a health plan perspective. Dis Manage Health Outcomes. 2003; 11(7):439–53.
- Gilmer T, Roze S, Valentine W, et al. Cost-effectiveness of diabetes case management for lowincome populations. Health Serv Res. 2007 In press.
- Garrett N, Martini EM. The boomers are coming: a total cost of care model of the impact of population aging on the cost of chronic conditions in the United States. Dis Manag. 2007; 10(2): 51–60. [PubMed: 17444790]
- Gilmer TP, O'Connor PJ, Manning WG, Rush WA. The cost to health plans of poor glycemic control. Diabetes Care. 1997; 20(12):1847–53. [PubMed: 9405905]
- Gilmer TP, O'Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. Diabetes Care. 2005; 28:59–64. [PubMed: 15616234]
- 14. Institute of Medicine. Crossing the quality chasm: A new health system for the 21st century. Washington DC: National Academy Press; 2001.
- 15. Institute of Medicine. To err is human. Washington, D.C: National Academy Press; 1999.
- McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003; 348(26):2635–45. [PubMed: 12826639]
- McGlynn EA. An evidence-based national quality measurement and reporting system. Med Care. 2003; 41(1 Suppl):I8–15. [PubMed: 12544812]
- Mangione-Smith R, DeCristofaro AH, Setodji CM, et al. The quality of ambulatory care delivered to children in the United States. N Engl J Med. 2007; 357(15):1515–23. [PubMed: 17928599]
- Bodenheimer T. High and rising health care costs. Part 1: seeking an explanation. Ann Intern Med. 2005; 142(10):847–54. [PubMed: 15897535]
- 20. Bodenheimer T. High and rising health care costs. Part 3: the role of health care providers. Ann Intern Med. 2005; 142(12 Pt 1):996–1002. [PubMed: 15968014]
- 21. Barr, M.; Ginsburg, J. The Advanced Medical Home: A Patient-Centered, Physician-Guided Model of Health Care. 2006. A Policy Monograph of the American College of Physicians.
- 22. Sia C, Tonniges TF, Osterhus E, Taba S. History of the medical home concept. Pediatrics. 2004; 113(5 Suppl):1473–8. [PubMed: 15121914]
- 23. Barr MS. The need to test the patient-centered medical home. JAMA. 2008; 300(7):834–5. [PubMed: 18714064]
- 24. Medical Home Initiatives for Children With Special Needs Project Advisory Committee. The medical home. Pediatrics. 2002; 110(1 Pt 1):184–6. [PubMed: 12093969]
- Rogers JC. The patient-centered medical home movement--promise and peril for family medicine. J Am Board Fam Med. 2008; 21(5):370–4. [PubMed: 18772290]
- Rosenthal TC. The medical home: growing evidence to support a new approach to primary care. J Am Board Fam Med. 2008; 21(5):427–40. [PubMed: 18772297]
- Starfield B. Access, primary care, and the medical home: rights of passage. Med Care. 2008; 46(10):1015–6. [PubMed: 18815520]
- Starfield B, Shi L. The medical home, access to care, and insurance: a review of evidence. Pediatrics. 2004; 113(5 Suppl):1493–8. [PubMed: 15121917]
- 29. Daaleman TP. The medical home: locus of physician formation. J Am Board Fam Med. 2008; 21(5):451–7. [PubMed: 18772299]
- DeVoe JE, Wallace LS, Pandhi N, Solotaroff R, Fryer GE Jr. Comprehending care in a medical home: a usual source of care and patient perceptions about healthcare communication. J Am Board Fam Med. 2008; 21(5):441–50. [PubMed: 18772298]
- 31. Beal, AC.; Doty, MM.; Hernandez, SE.; Shea, KK.; Davis, K. The Commonwealth Fund. Closing the Divide: How Medical Homes Promote Equity in Health Care: Results From The Commonwealth Fund 2006 Health Care Quality Survey. 2007 Jun.
- Bergeson SC, Dean JD. A systems approach to patient-centered care. JAMA. 2006; 296(23):2848– 51. [PubMed: 17179462]

- 33. Glasgow RE, Orleans CT, Wagner EH, Curry SJ, Solberg LI. Does the chronic care model serve also as a template for improving prevention? Milbank Quarterly. 2001; 79(4):579–612. iv–v. [PubMed: 11789118]
- O'Connor PJ, Sperl-Hillen JM, Pronk NP, Murray T. Primary care clinic-based chronic disease care: features of successful programs. Dis Manage Health Outcomes. 2001; 9(12):691–698.
- Feifer C, Ornstein SM, Nietert PJ, Jenkins RG. System supports for chronic illness care and their relationship to clinical outcomes. Top Health Inf Manage. 2001; 22(2):65–72. [PubMed: 11761794]
- Rothman AA, Wagner EH. Chronic illness management: what is the role of primary care? Ann Intern Med. 2003; 138(3):256–61. [PubMed: 12558376]
- Solberg LI, Asche SE, Margolis KL, Whitebird RR, Trangle MA, Wineman AP. Relationship between the presence of practice systems and the quality of care for depression. Am J Med Qual. 2008; 23(6):420–6. [PubMed: 19001099]
- McMullin ST, Lonergan TP, Rynearson CS. Twelve-month drug cost savings related to use of an electronic prescribing system with integrated decision support in primary care. J Manag Care Pharm. 2005; 11(4):322–32. [PubMed: 15871643]
- McMullin ST, Lonergan TP, Rynearson CS, Doerr TD, Veregge PA, Scanlan ES. Impact of an evidence-based computerized decision support system on primary care prescription costs. Ann Fam Med. 2004; 2(5):494–8. [PubMed: 15506587]
- Fischer MA, Vogeli C, Stedman M, Ferris T, Brookhart MA, Weissman JS. Effect of electronic prescribing with formulary decision support on medication use and cost. Arch Intern Med. 2008; 168(22):2433–9. [PubMed: 19064827]
- Fischer B, Rehm J. Illicit opioid use in the 21st century: witnessing a paradigm shift? Addiction. 2007; 102(4):499–501. [PubMed: 17362281]
- 42. Fischer MA, Avorn J. Potential savings from increased use of generic drugs in the elderly: what the experience of Medicaid and other insurance programs means for a Medicare drug benefit. Pharmacoepidemiol Drug Saf. 2004; 13(4):207–14. [PubMed: 15255087]
- Paulus RA, Davis K, Steele GD. Continuous innovation in health care: implications of the Geisinger experience. Health Aff (Millwood). 2008; 27(5):1235–45. [PubMed: 18780906]
- Patient Centered Primary Care Collaborative. A compilation of PCMH pikot and demonstration projects. Vol. December 15, 2008. 2008. Patient-Centered Medical Home Buyilding Evidence and Momentum.
- O'Connor, P.; Asche, S.; Hammory, B. Variation in diabetes quality of care across clinics: an assessment using electronic medical record data; Academy Health Annual Research Meeting; Orlando, FL. 2007;
- Gilmer TP, O'Connor PJ, Rush WA, et al. Relative impact of glycemic control and cardiovascular comobidty on subsequent resource use among adults with diabetes. Diabetes. 2004; 53(Suppl 2):A50.
- 47. O'Connor, P.; Goodman, M.; Maciosek, M. MN Health Services Research meeting. Relative costs and effectiveness of clinical strategies to treat type 2 diabetes mellitus. 1999 Feb 23.
- Pronk N, Goodman M, O'Connor P, Martinson B. Relationship between modifiable health risks and short-term health care charges. Jama. 1999; 282(23):2235–9. [PubMed: 10605975]
- 49. O'Connor PJ, Rush WA, Pronk NP, Cherney LM. Identifying diabetes mellitus or heart disease among health maintenance organization members: sensitivity, specificity, predictive value, and cost of survey and database methods. Am J Manag Care. 1998; 4(3):335–42. [PubMed: 10178496]
- 50. Evaulation and Management Services Guide. Centers for Medicare & Medicaid Services (CMS); 2009.
- Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA. 2002; 288(15):1909–14. [PubMed: 12377092]
- 52. Solberg LI, Asche SE, Pawlson LG, Scholle SH, Shih SC. Practice systems are associated with high-quality care for diabetes. Am J Manag Care. 2008; 14(2):85–92. [PubMed: 18269304]
- Scholle SH, Pawlson LG, Solberg LI, et al. Measuring practice systems for chronic illness care: accuracy of self-reports from clinical personnel. Jt Comm J Qual Patient Saf. 2008; 34(7):407–16. [PubMed: 18677872]

- Demirtas H, Hedeker D. Gaussianization-based quasi-imputation and expansion strategies for incomplete correlated binary responses. Stat Med. 2006
- Preda C, Duhamel A, Picavet M, Kechadi T. Tools for statistical analysis with missing data: application to a large medical database. Stud Health Technol Inform. 2005; 116:181–6. [PubMed: 16160256]
- 56. Yang X, Belin TR, Boscardin WJ. Imputation and variable selection in linear regression models with missing covariates. Biometrics. 2005; 61(2):498–506. [PubMed: 16011697]
- 57. Medicare program; revisions to payment policies, five-year review of work relative value units, changes to the practice expense methodology under the physician fee schedule, and other changes to payment under part B; revisions to the payment policies of ambulance services under the fee schedule for ambulance services; and ambulance inflation factor update for CY. Final rule with comment period. Fed Regist. 2006; 71(231):69623–70251. [PubMed: 17171850]
- Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2006 and certain provisions related to the Competitive Acquisitions Program of outpatient drugs and biologicals under Part B. Final rule with comment. Fed Regist. 2005; 70(223):70115– 476. [PubMed: 16299947]
- Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2005. Final rule with comment period. Fed Regist. 2004; 69(219):66235–915. [PubMed: 15551493]
- 60. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2003 and inclusion of registered nurses in the personnel provision of the critical access hospital emergency services requirement for frontier areas and remote locations. Final rule with comment period. Fed Regist. 2002; 67(251):79965–80184. [PubMed: 12510665]
- Medicare program; criteria for submitting supplemental practice expense survey data under the physician fee schedule. Interim final rule with comment period. Fed Regist. 2002; 67(125):43555– 8. [PubMed: 12120662]
- 62. Medicare program; revisions to payment policies and five-year review of and adjustments to the relative value units under the physician fee schedule for calendar year 2002. Final rule with comment period. Fed Regist. 2001; 66(212):55245–503. [PubMed: 11760761]
- 63. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2001. Health Care Financing Administration (HCFA), HHS. Final rule with comment period. Fed Regist. 2000; 65(212):65376–603. [PubMed: 11503688]
- 64. Medicare program; revisions to payment policies under the physician fee schedule for calendar year 2000. Health Care Financing Administration (HCFA), HHS. Final rule with comment period. Fed Regist. 1999; 64(211):59380–590. [PubMed: 11010693]
- 65. Ingenix. Symmetry Episode Treatment Groups®. 2008; 2008
- 66. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J Health Econ. 2001; 20(4):461–94. [PubMed: 11469231]
- 67. Manning WG. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ. 1998; 17(3):283–95. [PubMed: 10180919]
- 68. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005; 24(3):465–88. [PubMed: 15811539]
- 69. Zeileis A. Object-oriented Computation of Sandwich Estimators. Journal of Statistical Software. 2006; 16(9):1–16.
- 70. Zeileis A. Econometric Computing with HC and HAC Covariance Matrix Estimators. Journal of Statistical Software. 2004; 11(10):1–17.
- Gilles ME, Strayer LJ, Leischow R, Feng C, Menke JM, Sechrest L. Awareness and implementation of tobacco dependence treatment guidelines in Arizona: Healthcare Systems Survey 2000. Health Res Policy Syst. 2008; 6:13. [PubMed: 19099593]
- Scholle SH, Roski J, Adams JL, et al. Benchmarking physician performance: reliability of individual and composite measures. Am J Manag Care. 2008; 14(12):833–8. [PubMed: 19067500]
- 73. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness. Jama. 2002; 288(14):1775–9. [PubMed: 12365965]

#### Table 1

Elements of the PPC-RS by Domain of the Chronic Care Model

| Chronic Care Model Domain    | Elements of the PPC-RS                     |
|------------------------------|--|
| Health Care Organization     | Individual Feedback                        |
|                              | Performance Measurement                    |
|                              | Formal Quality Improvement Activities      |
| Delivery System Redesign     | Advanced Access                            |
|                              | Primary Care Teams                         |
|                              | Scheduling System for Physician Continuity |
|                              | Non-MD Educator                            |
|                              | Nurse Manager                              |
|                              | Pre-Visit Planning                         |
|                              | After Visit Follow-up                      |
|                              | Missed Appointments Follow-up              |
| Clinical Information Systems | Disease Registry                           |
|                              | Problem Lists                              |
|                              | Medication Lists                           |
|                              | Process Flow Sheets                        |
|                              | Checklists of Tests or Interventions       |
|                              | Patient Assessment Questionnaire           |
|                              | Clinical Test Tracking                     |
|                              | Referral Tracking                          |
|                              | Electronic Medical Record                  |
| Decision Support             | Clinical Guidelines                        |
|                              | Clinical Guidelines Preventive Services    |
|                              | Clinician Reminders for Diabetes Care      |
|                              | Clinician Reminders for Preventive Service |
|                              | Clinician Reminders for Risk Assessments   |
|                              | Clinician Reminders for Counseling         |
|                              | Abnormal Test Alerts                       |
|                              | Abnormal Test Protocols                    |
| Self-Management Support      | Patient Reminders for Diabetes Care        |
|                              | Patient Reminders for Preventive Services  |
|                              | Self Management Plans and Materials        |
|                              | Self Management Programs                   |
|                              | Individualized Patient Education           |
|                              | Electronic Patient Communication           |
|                              | Risk Factor Screening                      |

#### Table 2

Patient Demographics, Clinical Characteristics, and Utilization (N=2008)

|  | Ν    | Mean (SD) or Percent |
|--|------|----------------------|
| Demographics                             |      |                      |
| Patient Age                              | 2008 | 54.1 (9.3)           |
| Male                                     |      | 58                   |
| Clinical Characteristics                 |      |                      |
| Systolic BP                              | 1965 | 126.3 (15.1)         |
| A1c                                      | 1916 | 7.3 (1.5)            |
| LDL                                      | 1825 | 97.5 (42.6)          |
| BMI*                                     | 969  | 34.4 (7.6)           |
| ASPIRIN USE (%)                          | 2008 | 71%                  |
| Comorbidities                            |      |                      |
| CHF (%)                                  | 2008 | 23%                  |
| CVD (%)                                  | 2008 | 9%                   |
| ASTHMA (%)                               | 2008 | 10%                  |
| COPD (%)                                 | 2008 | 5%                   |
| HTN (%)                                  | 2008 | 52%                  |
| Utilization (reported in HPRRVs)         |      |                      |
| Ambulatory Management Costs              | 2008 | \$3,116 (\$2,399)    |
| Potentially Avoidable Costs <sup>+</sup> | 781  | \$2,623 (4,763)      |
| Total Costs                              | 2008 | \$4,137 (\$4,211)    |
| Outpatient Pharmacy                      |      |                      |
| Number of Glucose Scripts                | 2008 | 11.3 (11.1)          |
| % Generic <sup>**</sup>                  | 1529 | 60% (39%)            |
| Number of Hypertension Scripts           | 2008 | 10.2 (12.1)          |
| % Generic <sup>**</sup>                  | 1323 | 80% (33%)            |
| Number of Cholesterol Scripts            | 2008 | 5.8 (6.91)           |
| % Generic <sup>**</sup>                  | 1212 | 12% (27%)            |
| Number of Other Scripts                  | 2008 | 18.98 (22.42)        |
| % Generic <sup>**</sup>                  | 1687 | 47% (32%)            |

\*\* Among those with at least one Script

BMI= Body mass index

<sup>+</sup>Among 781 episodes with utilization

Page 13

Author Manuscript

Table 3

Variation in Utilization and Systems Across Medical Groups (n=27)\*

| Implete of Complete Episodes       63       39       179         Idilization*       Ambulatory Management Costs       52.577       55.373         Potentially Avoidable Costs*       51.534       54.34         Potentially Avoidable Costs*       51.534       54.36         % of Episodes with Utilization       39%       59%       55.46         % of Episodes with Utilization       39%       57.36       55.36         % of Episodes with Utilization       39%       57.36       55.36         Patients with CHP (%)       23.3%       25.9%       55.3%       55.3%         Patients with COPD (%)       81.%       4.7%       55.3%       55.3%         Patients with COPD (%)       81.%       4.7%       10.8%         Patients with HTN (%)       49.6%       11.8%       83.3%         Patients with HTN (%)       112%       25.3%       25.3%         Patients with HTN (%)       112%       25.3%       25.3%         Patients with HTN (%)       12%       27.4%       25.3%         Patients with HTN (%)       12%       27.4%       25.3%         Patients with HTN (%)       12%       27.4%       27.4%         Patients with HTN (%)       27.4%       27.4%   |                            |  | Mean    | Std Dev | Max    | Min     |
|--|----------------------------|--|---------|---------|--------|---------|
| Ambulatory Management Costs $$2,577$ Potentially Avoidable Costs+ $$1,524$ $$1,534$ % of Episodes with Utilization $39\%$ $39\%$ % of Episodes with Utilization $39\%$ $39\%$ % of Episodes with Utilization $39\%$ $39\%$ Patients with CDSts $$3,255$ $$2,33\%$ Patients with CHF (%) $$1,9\%$ $$2,3\%$ Patients with CVD (%) $$1,9\%$ $$2,3\%$ Patients with COPD (%) $$2,3\%$ $$2,0\%$ Patients with COPD (%) $$2,3\%$ $$2,0\%$ Number of Glucose Scripts** $$1,2\%$ $$2,0\%$ Number of Cholesterol Scripts** $$2,0\%$ $$2,0\%$ Number of Other Scripts** $$2,0\%$ </th <th></th> <th>Number of Complete Episodes</th> <th>63</th> <th>39</th> <th>179</th> <th>8</th> |                            | Number of Complete Episodes              | 63      | 39      | 179    | 8       |
| Potentially Avoidable Costs <sup>+</sup> $$1,524$ $$1,534$ % of Episodes with Utilization $39\%$ $39\%$ % of Episodes with Utilization $39\%$ $39\%$ Total Costs $$3,242$ $$3,265$ Patients with CHF (%) $$5,3,265$ $$2,7\%$ Patients with CND (%) $$1,9\%$ $$2,7\%$ Patients with ASTHMA (%) $$1,9\%$ $$2,7\%$ Patients with COPD (%) $$1,9\%$ $$2,7\%$ Patients with HTN (%) $$2,3\%$ $$2,7\%$ Patients with COPD (%) $$2,9\%$ $$11.8\%$ Number of Glucose Scripts** $$12$ $$2,0\%$ % Generic**** $$2,0\%$ $$2,0\%$   | Utilization*               | Ambulatory Management Costs              | \$2,641 | \$2,577 | \$531  | \$4,299 |
| % of Episodes with Utilization $39\%$ $39\%$ Total Costs $53,242$ $53,265$ Patient Age $55$ $2$ Patient swith CHF (%) $2.3\%$ $2.7\%$ Patients with CHF (%) $2.3\%$ $2.7\%$ Patients with CHF (%) $8.1\%$ $4.7\%$ Patients with ASTHMA (%) $8.1\%$ $4.7\%$ Patients with HTN (%) $4.9.6\%$ $11.8\%$ Number of Glucose Scripts ** $12$ $2$ % Generic *** $63.0\%$ $20.6\%$ Number of Hypertension Scripts ** $12$ $4$ % Generic *** $97.8\%$ $8.5\%$ Number of Cholesterol Scripts ** $12$ $4$ % Generic *** $0.0\%$ $0.0\%$ % Generic *** $12$ $5.5$ % Generic *** $12$ $7.4$ % Generic *** $16$ $5$ % Generic *** $0.0\%$ $0.0\%$ % Generic *** $1.5$ $7.4$ % Generic *** $16$ $5$ % Generic *** $16$ $5$ % Gener   |                            | Potentially Avoidable Costs <sup>+</sup> | \$1,524 | \$1,534 | \$428  | \$2,206 |
| Total Costs $$3,3,242$ $$3,3,265$ Patient Age $$53$ $2$ Patients with CHF (%) $$1,96$ $2,7\%$ Patients with CVD (%) $8.1\%$ $5.3\%$ Patients with ASTHMA (%) $8.1\%$ $5.3\%$ Patients with ASTHMA (%) $8.1\%$ $5.3\%$ Patients with COPD (%) $8.1\%$ $5.3\%$ Patients with COPD (%) $4.8\%$ $5.3\%$ Patients with HTN (%) $4.9.6\%$ $11.8\%$ Patients with HTN (%) $49.6\%$ $11.8\%$ Number of Glucose Scripts** $12$ $2$ $\%$ Genetic*** $63.0\%$ $20.6\%$ Number of Hypertension Scripts** $12$ $4$ $\%$ Genetic**** $0.0\%$ $0.0\%$ $\%$ Genetic**** $0.0\%$ $0.0\%$ $\%$ Genetic**** $16$ $5$ $\%$ Genetic*** $16$ $5$ $\%$ Genetic**** $16$ $5$ $\%$ Genetic**** $16$ $5$ $\%$ Genetic*** $16$ $5$ $\%$ denetic**** $16$ $5$  |                            | % of Episodes with Utilization           | 39%     | 39%     | 12%    | 75%     |
| Patient Age       55       2         Patients with CHF (%) $2.3\%$ $2.7\%$ Patients with CVD (%) $8.1\%$ $5.3\%$ Patients with ASTHMA (%) $8.1\%$ $4.7\%$ Patients with ASTHMA (%) $8.1\%$ $5.3\%$ Patients with HTN (%) $4.9.6\%$ $11.8\%$ Number of Glucose Scripts ** $12$ $2$ % Generic *** $63.0\%$ $20.6\%$ Number of Hypertension Scripts ** $12$ $4$ % Generic *** $97.8\%$ $8.5\%$ Number of Cholesterol Scripts ** $12$ $4$ % Generic *** $0.0\%$ $0.0\%$ % Generic *** $0.0\%$ $0.0\%$ % Generic *** $16$ $5$ % Generic *** $16$ $5$ % Generic *** $16$ $5$ % at the fold (%) $56.3$ $11.3\%$ % at 2 or more Goal (%) $56.3$ $11.3$ % at 2 or more Goals ** $56.3$ $11.3$ % at 2 or more Goals ** $53.3$ $7.4$  |                            | Total Costs                              | \$3,242 | \$3,265 | \$544  | \$4,768 |
| Patients with CHF (%) $2.3\%$ $2.7\%$ Patients with CVD (%) $8.1\%$ $5.3\%$ Patients with ASTHMA (%) $8.1\%$ $4.7\%$ Patients with COPD (%) $8.1\%$ $4.7\%$ Patients with COPD (%) $8.1\%$ $3.7\%$ Patients with COPD (%) $4.8\%$ $3.7\%$ Patients with COPD (%) $4.8\%$ $3.7\%$ Patients with COPD (%) $4.8\%$ $3.7\%$ Patients with HTN (%) $4.8\%$ $3.7\%$ Patients with HTN (%) $4.8\%$ $3.7\%$ Number of Glucose Scripts** $12$ $2$ $\%$ Generic*** $97.8\%$ $8.5\%$ Number of Cholesterol Scripts** $97.8\%$ $8.5\%$ Number of Cholesterol Scripts** $97.8\%$ $8.5\%$ Number of Cholesterol Scripts** $97.8\%$ $11.3\%$ $\%$ Generic*** $16$ $5$ $\%$ deneric*** $74.4\%$ $11.3\%$ Patients at BP Goal (%) $56.3$ $11.0$ Patients at LDL Goal (%) $53.0$ $11.3$ $\%$ at 2 or more Goals** $73.0$ $73.0$ $\%$ at 2 or more Goals** $73.0$ $70$  | Demographics               | Patient Age                              | 55      | 2       | 59     | 50      |
| Patients with CVD (%) $8.1\%$ $5.3\%$ Patients with ASTHMA (%) $8.1\%$ $4.7\%$ Patients with COPD (%) $4.8\%$ $3.7\%$ Patients with HTN (%) $49.6\%$ $11.8\%$ Number of Glucose Scripts** $12$ $2$ % Generic*** $63.0\%$ $20.6\%$ Number of Hypertension Scripts** $12$ $4$ % Generic*** $97.8\%$ $8.5\%$ Number of Cholesterol Scripts** $12$ $4$ % Generic*** $97.8\%$ $8.5\%$ Number of Cholesterol Scripts** $12$ $4$ % Generic*** $0.0\%$ $0.0\%$ % Generic*** $16$ $5$ % Generic*** $16$ $5$ % at the following state of $0.0\%$ $7.4$ Patients at BP Goal (%) $56.3$ $11.0$ Patients at LDL Goal (%) $63.0$ $11.3$ % at 2 or more Goals** $32.3$ $8.2$  |                            | Patients with CHF (%)                    | 2.3%    | 2.7%    | 12.5%  | 0.0%    |
| Patients with ASTHMA (%) $8.1\%$ $4.7\%$ Patients with COPD (%) $4.8\%$ $3.7\%$ Patients with HTN (%) $4.8\%$ $3.7\%$ Patients with HTN (%) $49.6\%$ $11.8\%$ Number of Glucose Scripts** $12$ $2$ $\%$ Generic*** $63.0\%$ $20.6\%$ Number of Hypertension Scripts** $12$ $4$ $\%$ Generic*** $97.8\%$ $8.5\%$ Number of Cholesterol Scripts** $9$ $1$ $\%$ Generic*** $0.0\%$ $0.0\%$ $\%$ Generic*** $16$ $5$ $\%$ deneric*** $16$ $5$ $\%$ deneric*** $16$ $5$ $\%$ deneric*** $16$ $5$ $\%$ deneric*** $74.4\%$ $11.3\%$ $\%$ deneric*** $74.4\%$ $11.3\%$ $\%$ deneric*** $73.6.3$ $11.0$ $\%$ deneric*** $73.6.3$ $11.0$ $\%$ deneric*** $73.6.3$ $11.0$ $\%$ deneric*** $73.0$ $73.6.3$ $\%$ at 2 or more Goals** $73.0$ $70$ $\%$ at 3 Goals** $32.3$ $8.2$   |                            | Patients with CVD (%)                    | 8.1%    | 5.3%    | 25.0%  | 0.0%    |
| Patients with COPD (%) $4.8\%$ $3.7\%$ Patients with HTN (%) $49.6\%$ $11.8\%$ Number of Glucose Scripts ** $12$ $2$ % Generic *** $63.0\%$ $20.6\%$ % Generic *** $97.8\%$ $8.5\%$ Number of Hypertension Scripts ** $12$ $4$ % Generic *** $97.8\%$ $8.5\%$ % Generic *** $97.8\%$ $8.5\%$ Number of Cholesterol Scripts ** $12$ $4$ % Generic *** $97.8\%$ $8.5\%$ % Generic *** $97.8\%$ $8.5\%$ % Generic *** $97.8\%$ $97.8\%$ % Generic *** $97.8\%$ $97.8\%$ % Generic *** $97.8\%$ $97.8\%$ % deneric *** $97.8\%$ $7.9\%$ % deneric *** $97.8\%$   |                            | Patients with ASTHMA (%)                 | 8.1%    | 4.7%    | 16.7%  | 0.0%    |
| Patients with HTN (%) $49.6\%$ $11.8\%$ Number of Glucose Scripts ** $12$ $2$ % Generic *** $63.0\%$ $20.6\%$ Number of Hypertension Scripts ** $12$ $4$ % Generic *** $97.8\%$ $8.5\%$ Number of Cholesterol Scripts ** $9$ $1$ % Generic *** $97.8\%$ $8.5\%$ Number of Cholesterol Scripts ** $9$ $1$ % Generic *** $97.8\%$ $8.5\%$ Number of Cholesterol Scripts ** $16$ $5$ % Generic *** $166$ $5$ % Generic *** $166$ $5$ % Generic *** $166$ $5$ % at the foldow $74.4\%$ $11.3\%$ % at the foldow $73.6$ $74$ Patients at BP Goal (%) $78.5$ $74$ Patients at LDL Goal (%) $73.0$ $70$ % at 2 or more Goals ** $73.0$ $70$   |                            | Patients with COPD (%)                   | 4.8%    | 3.7%    | 10.8%  | 0.0%    |
| Number of Glucose Scripts $**$ 12       2         % Generic $***$ 63.0%       20.6%         Number of Hypertension Scripts $**$ 12       4         % Generic $***$ 97.8%       8.5%         % Generic $***$ 9.0%       0.0%         % Generic $***$ 9.0%       0.0%         % Generic $***$ 16       5         % Generic $***$ 44.4%       11.3%         Patients at BP Goal (%)       56.3       11.0         Patients at LDL Goal (%)       78.5       7.4         Patients at LDL Goal (%)       63.0       11.3         % at 2 or more Goals $**$ 73.0       70         % at 2 or more Goals $**$ 32.3       8.2  |                            | Patients with HTN (%)                    | 49.6%   | 11.8%   | 83.3%  | 25.0%   |
| % Generic***       63.0%       20.6%         Number of Hypertension Scripts**       12       4 $%$ Generic***       97.8%       8.5%         Number of Cholesterol Scripts**       9       1 $%$ Generic***       0.0%       0.0% $%$ Generic***       16       5 $%$ Generic***       16       5 $%$ Generic***       44.4%       11.3%         Patients at BP Goal (%)       78.5       7.4         Patients at BP Goal (%)       78.5       7.4         Patients at LDL Goal (%)       63.0       11.3 $%$ at 2 or more Goals**       73.0       7.0 $%$ at 3 Goals**       32.3       8.2  | <b>Outpatient Pharmacy</b> | Number of Glucose Scripts**              | 12      | 2       | 15     | 4       |
| Number of Hypertension Scripts $**$ 12       4         % Generic $***$ 97.8%       8.5%         % Generic $***$ 97.8%       8.5%         Number of Cholesterol Scripts $**$ 9       1         % Generic $***$ 0.0%       0.0%         % Generic $***$ 16       5         % Generic $***$ 44.4%       11.3%         Patients at BP Goal (%)       76.3       11.0         Patients at ALc Goal (%)       78.5       7.4         Patients at LDL Goal (%)       73.0       7.0         % at 2 or more Goals $**$ 73.0       7.0         % at 3 Goals $**$ 32.3       8.2   |                            | % Generic***                             | 63.0%   | 20.6%   | 100.0% | 0.0%    |
| % Generic*** $97.8%$ $8.5%$ Number of Cholesterol Scripts** $9$ $1$ $%$ Generic*** $0.0%$ $0.0%$ $%$ Generic*** $16$ $5$ $%$ Generic*** $16$ $5$ $%$ Generic*** $44.4%$ $11.3%$ $%$ Generic*** $44.4%$ $11.3%$ $%$ Generic*** $74.4%$ $11.3%$ $%$ Greeric*** $74.4%$ $11.3%$ $%$ Greeric*** $74.4%$ $11.3%$ $%$ drients at Alc Goal ( $%$ ) $56.3$ $11.0$ Patients at Alc Goal ( $%$ ) $78.5$ $7.4$ Patients at LDL Goal ( $%$ ) $63.0$ $11.3$ $%$ at 2 or more Goals** $73.0$ $7.0$ $%$ at 3 or more Goals** $32.3$ $8.2$   |                            | Number of Hypertension Scripts**         | 12      | 4       | 23     | 9       |
| Number of Cholesterol Scripts**       9       1         % Generic*** $0.0\%$ $0.0\%$ % Generic*** $16$ 5         Number of Other Scripts** $16$ 5         % Generic*** $44.4\%$ $11.3\%$ Patients at BP Goal (%) $56.3$ $11.0$ Patients at A1c Goal (%) $78.5$ $7.4$ Patients at LDL Goal (%) $78.5$ $7.4$ % at 2 or more Goals** $73.0$ $7.0$ % at 2 or more Goals** $32.3$ $8.2$   |                            | % Generic ***                            | 97.8%   | 8.5%    | 1.0%   | 55.0%   |
| % Generic***       0.0%       0.0%         Number of Other Scripts**       16       5         % Generic***       44.4%       11.3%         % Generic***       44.4%       11.3%         Patients at BP Goal (%)       56.3       11.0         Patients at A1c Goal (%)       78.5       7.4         Patients at LDL Goal (%)       63.0       11.3         % at 2 or more Goals**       73.0       7.0         % at 3 Goals**       32.3       8.2   |                            | Number of Cholesterol Scripts**          | 6       | 1       | 11     | 9       |
| Number of Other Scripts **         16         5           % Generic ***         44.4%         11.3%           % Generic ***         44.4%         11.3%           Patients at BP Goal (%)         56.3         11.0           Patients at A1c Goal (%)         78.5         7.4           Patients at LDL Goal (%)         63.0         11.3           % at 2 or more Goals **         73.0         7.0           % at 3 Goals **         32.3         8.2   |                            | % Generic***                             | 0.0%    | 0.0%    | 0.0%   | 0.0%    |
| % Generic***     44.4%     11.3%       Patients at BP Goal (%)     56.3     11.0       Patients at Alc Goal (%)     78.5     7.4       Patients at LDL Goal (%)     63.0     11.3       % at 2 or more Goals**     73.0     7.0       % at 3 Goals**     32.3     8.2  |                            | Number of Other Scripts**                | 16      | S       | 33     | 9       |
| Patients at BP Goal (%)       56.3       11.0         Patients at A1c Goal (%)       78.5       7.4         Patients at LDL Goal (%)       63.0       11.3         % at 2 or more Goals **       73.0       7.0         % at 3 Goals **       32.3       8.2   |                            | % Generic ***                            | 44.4%   | 11.3%   | 60.1%  | 12.1%   |
| ) 78.5 7.4<br>() 63.0 11.3<br>73.0 7.0<br>32.3 8.2   | Performance                | Patients at BP Goal (%)                  | 56.3    | 11.0    | 72.0   | 20.0    |
| <ul> <li>(3) 63.0 11.3</li> <li>73.0 7.0</li> <li>32.3 8.2</li> </ul>  |                            | Patients at A1c Goal (%)                 | 78.5    | 7.4     | 87.0   | 57.0    |
| 73.0 7.0<br>32.3 8.2   |                            | Patients at LDL Goal (%)                 | 63.0    | 11.3    | 87.0   | 41.0    |
| 32.3 8.2   |                            | % at 2 or more Goals **                  | 73.0    | 7.0     | 92.0   | 61.0    |
|  |                            | % at 3 Goals <sup>**</sup>               | 32.3    | 8.2     | 48.0   | 16.7    |

Author Manuscript

14.3 Min 25.0 12.5 12.5 32.2 32.2 100.0100.0100.062.5 95.8 Max 85.7 Std Dev 25.2 20.8 22.4 16.914.1 15.8 Mean 67.9 67.9 86.6 48.8 56.7 34.8 Clinical Information System Self-Management Systems **Overall PPC System Score** Delivery System Redesign Health Care Organization Decision Support **Practice Systems** 

Flottemesch et al.

Based upon each medical group's median costs per annual episode.

\*\* Denominator is total number of episodes for medical group

\*\*\* Among those with at least one script

<sup>+</sup> Among the 781 episodes with utilization

| 4        |  |
|----------|--|
| d)       |  |
| ž        |  |
| <u>_</u> |  |
| סי       |  |

Regression Results: Association between Clinical Practice Systems (PPC-RS score) and Medical Costs\*

| Total Costs                     | Coefficient       | p-value | Marginal Impact upon Costs** |         |                              |
|---------------------------------|-------------------|---------|------------------------------|---------|------------------------------|
| Health Care Organization        | -0.002            | 0.040   | (\$31.33)                    |         |                              |
| Delivery System Redesign        | -0.003            | 0.327   | \$29.15                      |         |                              |
| Clinical Information System     | -0.001            | 0.953   | (\$6.97)                     |         |                              |
| Decision Support                | -0.002            | 0.068   | (\$30.46)                    |         |                              |
| Self-Management Systems         | 0.001             | 0.553   | \$16.62                      |         |                              |
| Overall PPC System Score        | -0.002            | 0.205   | (\$27.39)                    |         |                              |
| Ambulatory Management Costs     | Coefficient       | p-value | Impact upon Costs**          |         |                              |
| Health Care Organization        | -0.001            | 0.251   | (\$12.65)                    |         |                              |
| Delivery System Redesign        | 0.001             | 0.007   | \$1.05                       |         |                              |
| Clinical Information System     | -0.001            | 0.00    | \$0.37                       |         |                              |
| Decision Support                | -0.001            | 0.967   | (\$0.50)                     |         |                              |
| Self-Management Systems         | 0.001             | 0.600   | \$5.57                       |         |                              |
| Overall PPC System Score        | -0.003            | 0.983   | (\$0.37)                     |         |                              |
|                                 | Likelihood of Use | of Use  | <b>Resource Utilization</b>  |         |                              |
| Potentially Avoidable Costs     | Coefficient       | p-value | Coefficient                  | p-value | Marginal Impact upon Costs** |
| Health Care Organization        | -0.029            | 0.036   | -0.019                       | 0.037   | (\$25.20)                    |
| Delivery System Redesign        | -0.002            | 0.490   | 0.011                        | 0.080   | \$0.89                       |
| Clinical Information System     | -0.002            | 0.523   | -0.010                       | 0.713   | (\$14.06)                    |
| Decision Support                | -0.066            | 0.023   | 0.001                        | 0.864   | (\$26.42)                    |
| Self-Management Systems         | -0.001            | 069.0   | 0.001                        | 0.655   | \$1.78                       |
| <b>Overall PPC System Score</b> | -0.006            | 0.153   | -0.001                       | 0.939   | (\$26.10)                    |

Med Care. Author manuscript; available in PMC 2015 November 11.

\*\* Based upon a 10% increase in the system score above the sample average